AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06545526
Drug: celecoxib and metformin combination
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
Trial: NCT04765657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously injected on Day 1, 90, and 270.
Trial: NCT04965597
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04537299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo looks exactly like the treatment drug, but it contains no active ingredient
Trial: NCT06042569
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06796868
Drug: GW117 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW117 Tablets 20mg orally once a day
Trial: NCT06796868
Drug: GW117 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW117 Tablets 20mg\*3 orally once a day
Trial: NCT06796868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo orally once a day
Trial: NCT06221683
Drug: Recombinant Human Granulocyte Colony-Stimulating Factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ug/kg/d, d1-10, s.c., qd, at 1pm
Trial: NCT06799611
Drug: CM336 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous CM336 administration step-up dosing Dose and frequency of CM336 according to the protocol
Trial: NCT04447911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo per os once daily for 30 days
Trial: NCT05456165
Drug: GRT-C901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An individualized neoantigen cancer vaccine using an adenovirus vector administered via intramuscular (IM) injections at Visit 1 and boost at Visit 6.
Trial: NCT05456165
Drug: GRT-R902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An individualized neoantigen cancer vaccine using a self-amplifying mRNA (samRNA) vector administered via IM injection at Visits 2, 4, 9, and 12.
Trial: NCT05456165
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to standard of care.
Trial: NCT05994157
Drug: CD38-SADA:177Lu-DOTA Complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA. Both will be administered as an IV infusions.
Trial: NCT06771180
Drug: Dara-CyBorD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dara-CyBorD will be used for newly diagnosed PGNMID, OR LCPT, OR TMA OR CGGN.
Trial: NCT05936281
Drug: Genakumab for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/1ml/ vial
Trial: NCT05851378
Drug: Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously at time of imaging
Trial: NCT04908865
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy will be continued.
Trial: NCT05435677
Drug: IcoSema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single dose of IcoSema administered subcutaneously, S.c. into the left thigh
Trial: NCT05673148
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive SOC chemotherapy
Trial: NCT06556394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via intrathecal injection
Trial: NCT06220019
Drug: TCM
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will perform subgroup analyses based on specific TCM interventions (such as Chinese patent medicines or external therapies) and the duration of TCM treatment (for example, comparing patients who receive continuous oral Chinese patent medicine for two months or more each year with those who do not). These analyses will assess the efficacy and safety of TCM.
Trial: NCT05694767
Drug: CM313 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous CM313 administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (CM 313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment.
Trial: NCT05494723
Drug: YB-1113
RxNorm normalized name: YTTERBIUM,YB-169
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
Trial: NCT05190471
Drug: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of BP1002 monotherapy
Trial: NCT05165407
Drug: IBI310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI310 1mg/kg be intravenously administered on Day 1 of every 2 cycle
Trial: NCT04742725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04742725
Drug: Prothione™ (6g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothione is a pro-Glutathione compound includes free-form amino acids
Trial: NCT06162169
Drug: Midazolam , Rosuvastatin calcium and digoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam , Rosuvastatin calcium and digoxin was administered orally
Trial: NCT06576765
Drug: AZD0780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1
Trial: NCT05716100
Drug: XEN1101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN1101 Capsules
Trial: NCT05621811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05886985
Drug: MatriPlax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
Trial: NCT05689047
Drug: M5717 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
Trial: NCT05689047
Drug: M5717 660 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult and adolescent participants with weight more than or equal to (\>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
Trial: NCT06506565
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion during wound care
Trial: NCT04859283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal saline (10 µL/kg) will be administered 30 min before the induction of anesthesia using a LMA MAD NasalTM -device. The dose is euvolemic to 1 µg/mL dexmedetomidine.
Trial: NCT04901871
Drug: 0.02 mg/kg, age<65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.
Trial: NCT04901871
Drug: 0.07 mg/kg, age<65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.
Trial: NCT04901871
Drug: 0.12 mg/kg, age<65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.
Trial: NCT04901871
Drug: 0.22 mg/kg, age<65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam of 0.22 mg/kg will be infused in patients aged\<65.
Trial: NCT04901871
Drug: 0.02 mg/kg, age≥65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
Trial: NCT04901871
Drug: 0.07 mg/kg, age≥65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
Trial: NCT04901871
Drug: 0.12 mg/kg, age≥65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam of 0.12 mg/kg will be infused in patients aged≥65
Trial: NCT04901871
Drug: 0.17 mg/kg, age≥65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
Trial: NCT04901871
Drug: 0.22 mg/kg, age≥65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
Trial: NCT04901871
Drug: 0.27 mg/kg, age≥65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
Trial: NCT06453902
Drug: TGRX-678
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally
Trial: NCT05191706
Drug: Prednisolone Acetate Ophthalmic
RxNorm normalized name: prednisolone acetate Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical administration four times a day for 28 days, followed by treatment taper
Trial: NCT05369533
Drug: Sinemet Pill
RxNorm normalized name: Sinemet Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet 25/100 will be taken 1 hour prior to TR, for the first 18 sessions.
Trial: NCT05369533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be taken 1 hour prior to TR, for the first 18 sessions.
Trial: NCT04084678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral tablets
Trial: NCT04909931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second arm : add on placebo for 12 weeks
Trial: NCT04923269
Drug: LY3532226
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04923269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05588804
Drug: Broncho-munal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
Trial: NCT05588804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
Trial: NCT06292806
Drug: FSH-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: controlled ovarian stimulation for IVF
Trial: NCT05198778
Drug: URC102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT04858074
Drug: Hypoestoxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Its active pharmaceutical ingredient (API) is Hypoestoxide, discovered in 1983, which was recently shown to be active against alpha synuclein and was very effective in modifying disease progression in a transgenic mouse model of PD
Trial: NCT04776044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching tablets for oral intake
Trial: NCT04574024
Drug: NBT-NM108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS Patients received NBT-NM108 at 60 g/day.
Trial: NCT05116787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally twice daily
Trial: NCT05204667
Drug: 380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (2 oral tablets 4 times/day up to 7 days (i.e., every 6 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
Trial: NCT05204667
Drug: 380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (2 oral tablets 6 times/day up to 7 days (i.e., every 4 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
Trial: NCT05159830
Drug: Placebo oral oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of similar cannabidiol galenic form
Trial: NCT00004739
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05061706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsules administered orally, once daily.
Trial: NCT06557265
Drug: NKX019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKX019 is an investigational allogeneic CD19-Directed CAR NK
Trial: NCT06557265
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepletion
Trial: NCT05583669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT06190782
Drug: systemic therapy alone
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~First line:~i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)
Trial: NCT06160271
Drug: PET scan of 68Ga-FAPI
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).
Trial: NCT06642428
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
Trial: NCT05814354
Drug: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to label, as one option for Physician's Choice (determined before randomization).
Trial: NCT05875168
Drug: DS-3939a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One IV infusion Q3W on Day 1 of each 21-day cycle
Trial: NCT06637254
Drug: HSK31858
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma
Trial: NCT06637254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo comparator of study
Trial: NCT04872270
Drug: Caffeine Pill
RxNorm normalized name: caffeine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 week supply of 1000 mg caffeine given postoperatively as part of the pain regimen
Trial: NCT04872270
Drug: Percocet 10Mg-325Mg Tablet
RxNorm normalized name: Percocet 10mg-325mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given postoperatively as standard post-op pain management
Trial: NCT04924660
Drug: TXA127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA127 0.5 mg/kg/day infused 3 hours daily for 5 days or until hospital discharge whichever comes first.
Trial: NCT04924660
Drug: TRV027
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV027 12mg/h as a continuous 24-hour infusion, infused for 5 days or until hospital discharge whichever comes first.
Trial: NCT04924660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027, over 30 minutes for APN01.~Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Trial: NCT05275855
Drug: EDI048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Liquid
Trial: NCT04987307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by SC injection.
Trial: NCT05699811
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2, intravenous infusion every 4-6 weeks
Trial: NCT06264141
Drug: Nitric Oxide Releasing Solution
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
Trial: NCT06568367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, taken once daily
Trial: NCT05722938
Drug: Trimodulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP will be administered via IV infusion on 5 consecutive days
Trial: NCT05722938
Drug: Placebo (human albumin 1%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP will be administered via IV infusion on 5 consecutive days
Trial: NCT04777396
Drug: Semagludtide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
Trial: NCT04777396
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
Trial: NCT06644417
Drug: TQA3605 tablets plus NAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQA3605 tablets is core protein regulator
Trial: NCT05684731
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.~Administer beginning in Week 5 or Week 6.
Trial: NCT06644417
Drug: TQA3605 Placebo plus NAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without drug substance
Trial: NCT05587296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo orally once daily
Trial: NCT06200207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.
Trial: NCT05114265
Drug: OxyNorm
RxNorm normalized name: Oxynorm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of OxyNorm
Trial: NCT06205407
Drug: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured at Viatris
Trial: NCT06205407
Drug: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured at Neolpharma.
Trial: NCT05347693
Drug: Local standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local SoC in the country to be used as per local label
Trial: NCT04895631
Drug: 18F-Fluorocholine
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-time injection of 4-7 millicurie (mCi)
Trial: NCT05557812
Drug: eugenol based zinc oxide and Ferric Sulfate
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
Trial: NCT06576882
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose: 1 g\].
Trial: NCT05511909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
Trial: NCT04841200
Drug: Chinese medicine compound combined with symptomatic treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd.~Each type of granule will be given orally, twice a day, for 52 weeks.